<unk>  <unk>  is the development of<unk>  (a low platelet count), due to the administration of various forms of<unk> , an anticoagulant.<unk>  predisposes to thrombosis (the abnormal formation of blood clots inside a blood vessel) because platelets release microparticles that activate thrombin, thereby leading to thrombosis. When thrombosis is identified the condition is called<unk>  and thrombosis <unk> T).<unk>  is caused by the formation of abnormal antibodies that activate platelets. If someone receiving<unk>  develops new or worsening thrombosis, or if the platelet count falls,<unk>  can be confirmed with specific blood tests. The treatment of<unk>  requires stopping<unk>  treatment, and both protection from thrombosis and choice of an agent that will not reduce the platelet count any further. Several alternatives are available for this purpose; mainly used are danaparoid, fondaparinux, argatroban, and bivalirudin. While<unk>  was discovered in the 1930s,<unk>  was not reported until the 1960s.
Heparin-induced thrombocytopenia
Sticky platelet syndrome
Venom-induced consumption coagulopathy
Pseudo gray platelet syndrome
Drug-induced thrombocytopenic purpura
Gray platelet syndrome
Disseminated intravascular coagulation
Immune thrombocytopenic purpura